GLP-1 coverage in Michigan
Documented Medicaid fee-for-service status and insurance-mandate activity — not a decision for your member ID.
Sources last checked October 28, 2026
Spot an error? Report a correction
Medicaid (obesity / weight-loss)
KFF, "Medicaid Coverage of and Spending on GLP-1s", January 2026
This is the KFF January 2026 fee-for-service survey row for Michigan. Managed-care plans in the same state can differ. GLP-1s prescribed for type 2 diabetes are covered by every state Medicaid program regardless of this row.
Michigan Medicaid reduced coverage of GLP-1 drugs for obesity-only use starting January 1, 2026.
MDHHS Numbered Letter L 25-73 says coverage of GLP-1 medications prescribed solely to treat obesity, including continuation requests, was reduced for dates of service on or after January 1, 2026. Coverage for other indications was not changed.
Source: MDHHS Numbered Letter L 25-73 (Pharmacy), 2025-12-08
For obesity-only requests, the patient must be classified as morbidly obese, with documented failure of all other clinically appropriate weight-loss interventions including preferred anti-obesity agents, and coverage must be considered only as a measure to avert higher-cost bariatric surgery.
Source: MDHHS Numbered Letter L 25-73 (Pharmacy), 2025-12-08
Prior authorizations approved before January 1, 2026 are honored for the remaining six months authorized.
Source: MDHHS Numbered Letter L 25-73 (Pharmacy), 2025-12-08
Wegovy and Saxenda become non-preferred on Michigan's Single PDL for their other covered indications, which carries a $3 copayment instead of $1 for applicable beneficiaries.
Source: MDHHS Numbered Letter L 25-73 (Pharmacy), 2025-12-08
The University of Michigan Institute for Healthcare Policy and Innovation reports that eligibility under the new limits requires a BMI of 40 or higher, and that most existing users lose coverage when their six-month authorization ends. This is the university's summary; the MDHHS letter does not state a BMI number.
Source: University of Michigan IHPI: Expert Q&A on Michigan Medicaid's new GLP-1 limits, Date not shown on page
Diabetes
Coverage for GLP-1s for type 2 diabetes continues. IHPI also reports that Zepbound is covered for moderate to severe sleep apnea and Wegovy for people with overweight or obesity who have established cardiovascular disease or severe liver disease.
Source: University of Michigan IHPI: Expert Q&A on Michigan Medicaid's new GLP-1 limits, Date not shown on page
State insurance-mandate activity
No mandate activity found in our current tracking for Michigan. That is not a denial — in most cases your employer plan matters more than a state statute. Full list: state laws.
What to do with this
Medicaid survey rows and mandate bills are not a prior-authorization approval. Call the number on your ID card and ask whether the drug is covered for your diagnosis.
Full 5-step checklist →Related: All state pages · Medicaid by state · State laws · Cash-pay options